Last Updated on August 25, 2021 by The Health Master
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market tofacitinib extended release tablets, 11 mg and 22 mg in the United States.
Zydus was the first ANDA filer on tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength.
Tofacitinib extended-release tablets had annual sales of approximately $2,082 million in the United States for the year ending June 2021, according to IQVIA data.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
GSK gets USFDA nod for Jemperli to treat advanced solid Tumours
Lupin gets tentative USFDA nod for Brivaracetam tablets
Zydus Cadila gets USFDA nod for Mesalamine ER capsules
Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion
Alembic gets USFDA nod for Clomipramine HCL Capsules
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
Procedure to obtain license for manufacturing of Cosmetics
Latest Notifications regarding Pharmaceuticals
FDA cancels 28 chemist licences, suspends 146
High court denied bail in Drug seizure case
J&J submits application to CDSCO for study of Covid-19 vaccine on…
Don’t treat Covid with drug meant for livestock: USFDA
For informative videos by The Health Master, click on the below YouTube icon: